D.A. Davidson & Co’s Insys Therapeutics, Inc. INSY Stock Holding History

D.A. Davidson & Co’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1,300	Closed	-$13K	–	2477
2017 Q1	$13K	Buy	+1,300	New	+$13.9K	﹤0.01%	1962

Other funds holding INSY

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

FHAM

Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

D.A. Davidson & Co's INSY Position: Q2 2017 in Review

D.A. Davidson & Co sold out of Insys Therapeutics, Inc. (INSY) in Q2 2017, closing a stake of 1,300 shares — an estimated $13K sold.

D.A. Davidson & Co first reported a position in INSY in Q1 2017 and held it in 1 quarter. The position peaked at $13K in Q1 2017. 118 funds tracked by Wall St. Rank hold INSY as of Q2 2017.

D.A. Davidson & Co reported no remaining Insys Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
D.A. Davidson & Co sold 1,300 Insys Therapeutics, Inc. shares in Q2 2017, an estimated $13K.
D.A. Davidson & Co first reported a position in Insys Therapeutics, Inc. in Q1 2017 and held it in 1 quarter.
D.A. Davidson & Co's Insys Therapeutics, Inc. position peaked at $13K in Q1 2017.
118 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2017.

Based on D.A. Davidson & Co's 13F filing for Q2 2017, filed 11 Aug 2017.